GlassScriptPhysician profile
Terrell M Hemelt
NPI 1437177821
$6,122.77
in general payments reported to CMS, 2019-2025
21 companies · $1,722 in 2025
The $1,722 reported for 2025 was more than what 87% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $355 · 2021: $771 · 2022: $1,000 · 2023: $912 · 2024: $1,103 · 2025: $1,722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,737.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,665.86 | 2019-2025 | Clareon, Argos, Clareon Panoptix Pro |
| Glaukos Corporation | $431.39 | 2022-2025 | Idosetr |
| Abbvie INC. | $359.96 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $331.35 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Johnson & Johnson Surgical Vision, INC. | $318.61 | 2019-2025 | Tecnis Simplicity, Catalys System |
| Biotissue Holdings INC. | $220.85 | 2023-2025 | |
| Carl Zeiss Meditec USA, INC. | $206.45 | 2021 | |
| Dompe US, INC. | $120.39 | 2023-2025 | Oxervate |
| Oyster Point Pharma, INC. | $100.09 | 2022-2025 | Tyrvaya, Ryzumvi |
| Optos, INC. | $63.36 | 2022 | |
| New World Medical,INC. | $56.47 | 2025 | Ahmed Glaucoma Valve, Via360, Clearpath |
| Allergan, INC. | $51.46 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $35.45 | 2025 | Purified Cortrophin Gel |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $33.06 | 2020-2021 | |
| Kala Pharmaceuticals, INC. | $28.91 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $26.11 | 2025 | |
| Sight Sciences, INC. | $20.34 | 2024 | Omni Surgical System |
| Ocular Therapeutix, INC. | $16.41 | 2023 | Dextenza |
| Apellis Pharmaceuticals, INC. | $14.64 | 2025 | Syfovre |
| Boston Scientific Corporation | $11.90 | 2022 | |
| Rxsight INC | $9.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terrell Hemelt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.